title: [Metronomic chemotherapy in 2011: update and perspectives].
abstract: Angiogenesis is crucial for the growth and metastasis of many cancers. A series of new inhibitors of angiogenesis are now in intensive development. Recent preclinical studies suggest that frequent administration of certain conventional cytotoxic agents at low doses increases their putative antiangiogenic activity. Moreover, many clinical trials confirm efficacy of this metronomic chemotherapy in terms of clinical benefice and survival prolongation. Combining metronomic chemotherapy with hormonotherapy, angiogenesis inhibitors and radiotherapy increases efficacy. Many biomarkers are used to predict optimal drugs and appropriate use of them. This review describes experimental and clinical studies published and discuss its potential uses and limits.
authors.affiliation: CHU Hassan-II, service d'oncologie médicale, Fès, Maroc. zineb247@hotmail.com
authors.forename: Zineb
authors.initials: Z
authors.lastname: Benbrahim
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
authors.forename: Omar
authors.initials: O
authors.lastname: El Mesbahi
mesh_terms: D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000532:radiotherapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents